Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 + Nivolumab Injection [Opdivo]
Phase 1TerminatedDevelopment Stage
Bladder Cancer TNM Staging Primary Tumor (T) T2
Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3, Bladder Cancer TNM Staging Primary Tumor (T) T3A, Bladder Cancer TNM Staging Primary Tumor (T) T3B, Bladder Cancer TNM Staging Regional Lymph Node (N) N0, Bladder Cancer TNM Staging Regional Lymph Node (N) N1, Bladder Cancer TNM Staging Distant Metastasis (M) M0
Jan 2, 2019 → Dec 11, 2019
About Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 + Nivolumab Injection [Opdivo]
Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 + Nivolumab Injection [Opdivo] is a phase 1 stage product being developed by Bristol Myers Squibb for Bladder Cancer TNM Staging Primary Tumor (T) T2. The current trial status is terminated. This product is registered under clinical trial identifier NCT03518320. Target conditions include Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03518320 | Phase 1 | Terminated |
Competing Products
20 competing products in Bladder Cancer TNM Staging Primary Tumor (T) T2